local_hospital

Centre Hospitalier de la Région d'Annecy

Address
1 Avenue de l'Hôpital Metz-Tessy, 74374 Pringy, France

Centre Hospitalier de la Région d'Annecy - Oncology Research

The Centre Hospitalier de la Région d'Annecy is actively engaged in advancing precision oncology research, with particular emphasis on molecularly-defined lung cancer subtypes. The center participates in innovative therapeutic trials targeting specific genetic alterations in advanced malignancies.

  • Advanced non-small cell lung cancer with ROS1 fusion proteins
  • Targeted tyrosine kinase inhibitor therapy optimization
  • Molecular resistance mechanisms and treatment sequencing strategies

The center's oncology program demonstrates expertise in evaluating next-generation targeted therapies for patients who have experienced progression on initial treatment lines. Through participation in trials investigating agents like lorlatinib, the center contributes to understanding optimal therapeutic approaches in molecularly-selected patient populations, particularly those with rare oncogenic drivers requiring specialized management strategies.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
6
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
2
Outperforms 44% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
2sponsors
Outperforms 45% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier de la Région d'Annecy

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Comparison of mFOLFIRINOX Versus Platinum-Etoposide in First-Line Chemotherapy for Metastatic Grade 3 Gastroenteropancreatic Neuroendocrine CarcinomaCentre Hospitalier Universitaire De DijonPhase IIRecruitingOct 2024

IMP list

lock Showing 1 of 6 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cisplatin1Unknown2024-10-182024-10-18

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.